Aligos Therapeutics (ALGS) Cash from Operations (2019 - 2026)

Aligos Therapeutics has reported Cash from Operations for 8 years, with the latest figure at 23128000.0 in Q1 2026.

• For the quarter ending Q1 2026, Cash from Operations fell 10.61% year-over-year to 23128000.0; the trailing twelve-month figure through Mar 2026 stood at 84722000.0 (down 7.37% YoY), and the FY2025 full-year result was 82503000.0, down 2.18% from the prior year.
• Cash from Operations for Q1 2026 stood at 23128000.0, down from 21745000.0 in the prior quarter.
• The five-year high for Cash from Operations was 13616000.0 in Q2 2023, with the low at 25035000.0 in Q2 2022.
• Historically, Cash from Operations has averaged 20280000.0 across 5 years, with a median of 20434000.0 in 2022.
• Annual changes were most pronounced in 2022 — Cash from Operations surged 55.22% — and 2024, when it tumbled 43.16%.
• Aligos Therapeutics' Cash from Operations stood at 16783000.0 in 2022, then slumped by 35.01% to 22658000.0 in 2023, then increased by 18.78% to 18403000.0 in 2024, then dropped by 18.16% to 21745000.0 in 2025, then decreased by 6.36% to 23128000.0 in 2026.
• The last three Cash from Operations figures came in at 23128000.0 (Q1 2026), 21745000.0 (Q4 2025), and 24345000.0 (Q3 2025), per Business Quant data.